Lead Product(s): JT-09
Therapeutic Area: Dermatology Product Name: JT-09
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Titan Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2020
As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets. With the net proceeds from recent public the company is well positioned to progress preclinical development of its ProNeura-based pipeline and JT-09.